Valeant is selling its iNova Pharmaceuticals business for $930 million

Valeant is selling its iNova Pharmaceuticals business for $930 million


Valeant Pharmaceuticals International Inc said it would sell its iNova Pharmaceuticals business for $930 million, as Chief Executive Officer Joseph Papa steps up efforts to slash the embattled Canadian drugmaker's huge debt pile. The company's U.S.-listed shares were up about 3.5 percent at $12.60 in premarket trading on Thursday.



from Biotech News